Study Summary
This single-arm, single-center investigator-initiated trial (IIT) evaluates the safety, efficacy, and pharmacodynamic (PD)/pharmacokinetic (PK) profiles of CAR-T cells in patients with advanced solid tumors. Eligible subjects are followed until 12 months after infusion or until meeting treatment withdrawal criteria, whichever occurs first.
Want to learn more about this trial?
Request More InfoInterventions
CAR-TBIOLOGICAL
Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Dongguan Taixin Hospital | Dongguan | Guangdong | China |